Table 1.
Characteristics of 66 women with confirmed SARS-CoV-2 infectiona.
| No detectable SARS-CoV-2 in breast milk samples, n (%), N = 59 | Detectable SARS-CoV-2 in breast milk samples, n (%), N = 7 | P value | |
|---|---|---|---|
| Maternal age (median years [IQR]) | 35.80 [25.56, 46.67] | 32.28 [27.62, 38.66] | 0.120 |
| Race | 1.000 | ||
| Caucasian | 48 (84.21) | 7 (100.00) | |
| Black | 1 (1.75) | 0 (0.00) | |
| Asian | 5 (8.77) | 0 (0.00) | |
| Native American/Alaska native | 2 (3.51) | 0 (0.00) | |
| Multiracial | 1 (1.75) | 0 (0.00) | |
| Ethnicity | 0.528 | ||
| Hispanic | 5 (8.77) | 1 (14.29) | |
| Non-Hispanic | 52 (91.23) | 6 (85.71) | |
| US region of residence | 0.019 | ||
| North-East | 21 (35.59) | 1 (14.29) | |
| South | 15 (25.42) | 3 (42.86) | |
| Mid-West | 6 (10.17) | 3 (42.86) | |
| West | 17 (28.81) | 0 (0.00) | |
| BMI ≥ 30 | 20 (35.08) | 0 (0.00) | 0.096 |
| Underlying health conditionb | 15 (26.32) | 2 (28.57) | 1.000 |
| Symptomatic | 53 (89.83) | 6 (100.00) | 1.000 |
| Hospitalized | 6 (10.71) | 0 (0.00) | 1.000 |
| Treatment received: Remdesivir | 3 (5.26) | 0 (0.00) | 1.000 |
| Treatment received: ECMO | 2 (3.51) | 0 (0.00) | 1.000 |
| Source of infection | 0.517 | ||
| Household | 17 (29.31) | 3 (42.86) | |
| Community | 11 (18.97) | 2 (28.57) | |
| Occupational | 18 (31.03) | 2 (28.57) | |
| Unknown | 12 (20.69) | 0 (0.00) | |
| Infant age (median months [IQR]) | 7.97 [0.10, 35.28] | 9.63 [2.79, 15.65] | 0.498 |
| Infant sex | 0.691 | ||
| Male | 25 (43.86) | 4 (57.14) | |
| Female | 32 (56.14) | 3 (42.86) |
aSixty-five who tested positive by RT-PCR of the nasopharyngeal specimen and 1 without diagnostic testing whose breast milk sample was positive by RT-PCR.
bUnderlying medical conditions included the following: asthma, diabetes type II, heart defect, hypertension, hypothyroidism, irritable bowel disease, kidney defect, obesity, and “tachycardia”.